









Markets
/
Stocks
/
nasdaq-vygr
/

Voyager Therapeutics Inc

VYGR

4.485USD

+0.225+5.28%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

248.63MMarket Cap

LossP/E TTM



Voyager Therapeutics Inc

4.485

+0.225+5.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

68 / 507

Overall Ranking

177 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

15.667

Target Price

+268.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 95.57% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 80.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 40.07.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 65.00M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -2.30, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 44.49M shares, decreasing 7.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.21M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.94, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 5.20M, representing a year-over-year decrease of 82.42%, while its net profit experienced a year-over-year decrease of 229.18%.

Score

Industry at a Glance

Previous score

5.94

Change



Financials

6.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.88

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.30, which is -305.80% below the recent high of 4.73 and -62.82% above the recent low of -3.74.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Voyager Therapeutics Inc is 12.00, with a high of 30.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

15.667

Target Price

+267.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Voyager Therapeutics Inc

VYGR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.35, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 4.77 and the support level at 3.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.28

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.074

Buy

RSI(14)

63.622

Neutral

STOCH(KDJ)(9,3,3)

65.949

Neutral

ATR(14)

0.297

High Vlolatility

CCI(14)

76.392

Neutral

Williams %R

22.378

Buy

TRIX(12,20)

1.017

Sell

StochRSI(14)

24.147

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.256

Buy

MA10

4.182

Buy

MA20

3.808

Buy

MA50

3.529

Buy

MA100

3.377

Buy

MA200

4.067

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 80.20%, representing a quarter-over-quarter decrease of 1.64%. The largest institutional shareholder is The Vanguard, holding a total of 3.21M shares, representing 5.79% of shares outstanding, with 1.69% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Neurocrine Biosciences Inc

8.58M

Armistice Capital LLC

5.44M

+0.74%

EcoR1 Capital, LLC

3.92M

BlackRock Institutional Trust Company, N.A.

3.64M

+0.26%

The Vanguard Group, Inc.

Star Investors

3.21M

-0.14%

BlackRock Financial Management, Inc.

1.43M

+4.12%

Vestal Point Capital, LP

1.25M

+1.58%

Dimensional Fund Advisors, L.P.

1.50M

+8.38%

Geode Capital Management, L.L.C.

1.10M

+1.91%

Erste Asset Management GmbH

1.12M

+5.52%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.